{
  "url": "https://en.wikipedia.org/wiki/Boehringer_Ingelheim",
  "title": "Boehringer Ingelheim",
  "header": [
    [
      "Drug Name",
      []
    ],
    [
      "Description",
      []
    ],
    [
      "Potential Indication",
      []
    ],
    [
      "Testing Phase",
      []
    ]
  ],
  "data": [
    [
      [
        "Olodaterol",
        [
          "/wiki/Olodaterol"
        ]
      ],
      [
        "Long-acting beta-agonist",
        [
          "/wiki/Long-acting_beta-agonist"
        ]
      ],
      [
        "Chronic obstructive pulmonary disease ( COPD )",
        [
          "/wiki/Chronic_obstructive_pulmonary_disease"
        ]
      ],
      [
        "Approved",
        []
      ]
    ],
    [
      [
        "Tiotropium",
        [
          "/wiki/Tiotropium"
        ]
      ],
      [
        "Long acting muscarinic antagonist",
        []
      ],
      [
        "Cystic fibrosis ( CF ) / asthma . Already approved for chronic obstructive pulmonary disease ( COPD )",
        [
          "/wiki/Cystic_fibrosis",
          "/wiki/Asthma",
          "/wiki/Chronic_obstructive_pulmonary_disease"
        ]
      ],
      [
        "Approved",
        []
      ]
    ],
    [
      [
        "Nintedanib",
        [
          "/wiki/Nintedanib"
        ]
      ],
      [
        "Triple angiokinase inhibitor , simultaneously blocks VEGFR , FGFR , PDGFR",
        [
          "/wiki/VEGFR",
          "/wiki/FGFR",
          "/wiki/PDGFR"
        ]
      ],
      [
        "Idiopathic pulmonary fibrosis ( IPF ) / non-small cell lung cancer ( NSCLC ) / ovarian cancer",
        [
          "/wiki/Idiopathic_pulmonary_fibrosis",
          "/wiki/Non-small_cell_lung_cancer",
          "/wiki/Ovarian_cancer"
        ]
      ],
      [
        "Phase III",
        []
      ]
    ],
    [
      [
        "Afatinib",
        [
          "/wiki/Afatinib"
        ]
      ],
      [
        "Irreversible ErbB family blocker",
        [
          "/wiki/ErbB"
        ]
      ],
      [
        "Breast cancer / head and neck cancer . Already approved for non-small cell lung cancer ( NSCLC )",
        [
          "/wiki/Breast_cancer",
          "/wiki/Head_and_neck_cancer",
          "/wiki/Non-small_cell_lung_cancer"
        ]
      ],
      [
        "Phase III",
        []
      ]
    ],
    [
      [
        "Volasertib",
        [
          "/wiki/Volasertib"
        ]
      ],
      [
        "PLK1 antagonist",
        [
          "/wiki/PLK1"
        ]
      ],
      [
        "Various cancer types",
        []
      ],
      [
        "Phase III",
        []
      ]
    ],
    [
      [
        "Deleobuvir ( formerly BI 207127 )",
        [
          "/wiki/Deleobuvir"
        ]
      ],
      [
        "NS5B RNA-dependent polymerase inhibitor",
        [
          "/wiki/NS5B"
        ]
      ],
      [
        "Hepatitis C",
        [
          "/wiki/Hepatitis_C"
        ]
      ],
      [
        "Phase III",
        []
      ]
    ],
    [
      [
        "Faldaprevir ( formerly BI 201335 )",
        [
          "/wiki/Faldaprevir"
        ]
      ],
      [
        "NS3 / 4A protease inhibitor",
        [
          "/wiki/NS3_(HCV)",
          "/wiki/NS4A"
        ]
      ],
      [
        "Hepatitis C",
        [
          "/wiki/Hepatitis_C"
        ]
      ],
      [
        "Phase III",
        []
      ]
    ],
    [
      [
        "Empagliflozin",
        [
          "/wiki/Empagliflozin"
        ]
      ],
      [
        "SGLT-2 -inhibitor",
        [
          "/wiki/SGLT-2"
        ]
      ],
      [
        "Diabetes mellitus type II",
        [
          "/wiki/Diabetes_mellitus_type_II"
        ]
      ],
      [
        "Approved",
        []
      ]
    ],
    [
      [
        "Idarucizumab",
        [
          "/wiki/Idarucizumab"
        ]
      ],
      [
        "Humanized antibody fragment ( FAB ) , specific reversal agent to dabigatran",
        [
          "/wiki/Dabigatran"
        ]
      ],
      [
        "Reversal of dabigatran-induced anticoagulation in case of an emergency",
        [
          "/wiki/Anticoagulation"
        ]
      ],
      [
        "Phase III",
        []
      ]
    ]
  ],
  "section_title": "Products -- Product pipeline",
  "section_text": "Boehringer Ingelheim 's product pipeline targets lung disease , cancer , and hepatitis C. [ 40 ]",
  "uid": "Boehringer_Ingelheim_0"
}